8th February 2019 08:45 - 17:30 (GMT+00:00) GMT
This one-day event will cover the exciting concept of theranostics. This event will discuss the use of theranostics in the imaging and therapy of primarily oncological conditions. Our renowned international multidisciplinary faculty of expert oncologists, radiopharmacists, radiologists, physicists and nuclear medicine physicians will provide a comprehensive overview of imaging technology and therapies. Attendees will develop their skills in theranostics with talks covering radiological imaging, PET/CT, radionuclide therapy, regulatory requirements and new theranostic tracers. There will also be opportunities for discussions with our expert panel.
This event will be of interest to all nuclear medicine physicians, radiologists, oncologists, onco-surgeons, trainees, clinical physicists, technologists and healthcare managers.
BIR Plan 1 member £165
BIR Plan 2 member £125
BIR Trainee member £75
BIR Retired member £65
BIR Student member £65
We are very grateful to the following organisations for supporting this event.
Bayer’s Radiology business is well placed to be the partner of choice in helping NHS trusts to address the many challenges faced today including the increasing need for governance to demonstrate best practice and improving patient care within increasing financial constraints. With market-leading contrast media and power injector systems, Bayer is able to offer innovative patient care and with the addition of its informatics platform, it can support radiology departments in driving protocol standardisation and easily accessible audit data that enable departments to meet further challenges faced around contrast and radiation dose management. 0118 2063999 www.radiology.bayer.co.uk
Advanced Accelerator Applications (AAA) is an innovative radiopharmaceutical company developing, producing and commercializing molecular nuclear medicine theragnostics. Theragnostics is a strategy that can combine a single targeting compound with different isotopes in order to deliver diagnostic or therapeutic interventions. AAA is at the forefront of developing predictive, preventive and personalized tools and procedures that have the potential to radically transform healthcare. Our path to accomplishing this goal is by merging therapeutic and diagnostic approaches to advance early detection, treatment, and monitoring of diseases. AAA is developing a pipeline of theragnostic pairings for oncology indications. Specifically, the company’s theragnostic platform involves radiolabeling a targeting molecule – initially the somatostatin analogue, dotatate (oxodotereotide) – with either gallium Ga 68 for diagnostic use, or lutetium Lu 177 for therapy. Products based on this first theragnostic pairing include the diagnostics NETSPOT® (gallium Ga 68 dotatate) in the US and SomaKit TOC® (gallium (Ga 68) edotreotride) in Europe, and the therapeutic, Lutathera® (USAN: lutetium Lu 177 dotatate/INN: lutetium (177Lu) oxodotreotide), which is approved for use in Europe and the United States. Additional pairings in development target Gastrointestinal Stromal Tumors (GIST), and prostate and breast cancer. AAA is a leader in the production and commercialization of molecular nuclear diagnostic radiopharmaceuticals for Positron Emission Tomography (PET) and Single-Photon Emission Computed Tomography (SPECT). The Company currently markets 9 diagnostic products (8 in Europe and 1 in the US), mainly used in clinical oncology, cardiology, neurology and infectious/inflammatory diseases. AAA is a Novartis company.
Philips Healthcare is a leading supplier of diagnostic imaging systems and related services. Following the recent programme of acquisitions the company offers a comprehensive porfolio of healthcare products including conventional X-ray systems, dedicated systems for cardiovascular and interventional procedures; CT and MRI scanners, nuclear medicine, radiation therapy planning, echocardiography, digital ultrasound, patient cardiac monitoring equipment and PACS. www.medical.philips.com
The healthcare market is in ongoing transition and we see healthcare providers worldwide drive consolidation, an increasingly "industrial" logic of healthcare delivery, and a shift from treating illness to managing health – ultimately looking for ways to improve outcomes while reducing costs. We aspire to be the partner to help achieve this goal. To live up to our ambition, we are determined to answer the questions that drive your business development. To overcome lack of specialised staff, ensure consistent outcomes across an organisation, increase competitiveness, avoid profitability risks, and implement growth strategies, we are your partner that you can rely on to stand out with clinical excellence, operational efficiency, and financial profitability. www.siemens.co.uk/healthcare